Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.63 |
| ▸ | PDE2A | O00408 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SLC29A1 | Q99808 | 7/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.58 |
| ▸ | CD99 | P14209 | 1/20 | 0.54 |
| ▸ | PGK1 | P00558 | 1/20 | 0.53 |
| ▸ | PGK2 | P07205 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24233636 | 1.00 | ADORA2A (0.63) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL8970329 | 1.00 | ADORA2A (0.63) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL22430950 | 1.00 | ADORA2A (0.63) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL24233631 | 1.00 | ADORA2A (0.63) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL8970907 | 0.91 | ADORA2A (0.62) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL8970895 | 0.91 | ADORA2A (0.62) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| Nelarabine SCHEMBL9937290 | 0.90 | CYP2C19 (0.71) | ADORA2AADORA3ADORA1CYP2C19SLC29A1 | |
| Nelarabine SCHEMBL14031852 | 0.90 | CYP2C19 (0.71) | ADORA2AADORA3ADORA1CYP2C19SLC29A1 | |
| Nelarabine SCHEMBL18820 | 0.90 | CYP2C19 (0.71) | ADORA2AADORA3ADORA1CYP2C19SLC29A1 | |
| Nelarabine SCHEMBL20769831 | 0.90 | CYP2C19 (0.71) | ADORA2AADORA3ADORA1CYP2C19SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0417999-B1 | Antiviral compounds | WELLCOME FOUND (GB) | 1996-03-13 | — | — | EP | claimed |
| US-5420115-A | Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides | BURROUGHS WELLCOME CO. (US) | 1995-05-30 | — | — | US | claimed |
| EP-0417999-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | claimed |
| US-20220033432-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| EP-3939655-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020184677-A1 | ANTI-HEPATITIS B VIRUS AGENT | ダイキン工業株式会社 | 2020-09-17 | — | — | WO | disclosed |
| EP-0417999-B1 | Antiviral compounds | WELLCOME FOUND (GB) | 1996-03-13 | — | — | EP | disclosed |
| EP-0671410-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-09-13 | — | — | EP | disclosed |
| US-5420115-A | Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides | BURROUGHS WELLCOME CO. (US) | 1995-05-30 | — | — | US | disclosed |
| US-5420115-A | Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides | BURROUGHS WELLCOME CO. (US) | 1995-05-30 | — | — | US | disclosed |
| US-5175274-A | Treatment of HIV infections | BURROUGHS WELLCOME CO. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0285432-B1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-11-11 | — | — | EP | disclosed |
| EP-0417999-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
| EP-0285432-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033432-A1 | ANTI-HEPATITIS B VIRUS AGENT | SLC10A1, HAVCR2, FABP1 | ADORA2A 1834/4885ADORA3 1331/4885ADORA1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.